Company / Operating Cash Flow
Immix Biopharma, Inc. Operating Cash Flow History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$14.6M
FY2025
5-year range
-$14.6M / -$7.4M
FY2023-FY2025
Trend
-28.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from -$7M to -$15M over the past 2 years.
Based on SEC 10-K filings.
-$15M in FY2025.
Declined from -$7M to -$15M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow decreased 28.3% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.83 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$14.6M | -28.3% |
| FY2024 | -$11.4M | -53.5% |
| FY2023 | -$7.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026